Nucleolar G1 antigens as cancer targets

H. Busch, R. K. Busch, J. W. Freeman, A. Black, E. Rabinovsky, A. Chatterjee, A. B. Reddy, M. Yaneva

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Cancer cells and most normal resting cells have been readily differentiated for a century by morphologic and biologic criteria but biochemical and immunologic distinctions have not yet withstood the test of time. Although Warburg et al. had indicated that biochemical differences in glycolysis existed between cancer cells and other cells, it took almost 30 years to establish that these differences applied only to a limited spectrum of tumors. Moreover, careful analysis of the enzymes and substrates of glycolysis, the Krebs cycle, and hydrogen transport did not provide meaningful differences between cancer cells and other cells. Isozyme variants, particularly fetal isozymes in cancer tissues, were reported, but results were variable in different studies and different tumors, as now found for 'oncogenes'.

Original languageEnglish (US)
Pages (from-to)141-151
Number of pages11
JournalJournal of Tumor Marker Oncology
Issue number3
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Nucleolar G1 antigens as cancer targets'. Together they form a unique fingerprint.

Cite this